博客
Insilico Medicine Initiates First-in-Human Study of AI-discovered Drug
Insilico discovered a Novel disease mechanism, identified a Novel target, and designed a Novel molecule validated in preclinical experiments
We are very happy to be presenting our approach to generative chemistry and the Chemistry42 platform at the NVIDIA GTC 2021 and the application of this platform which enabled the nomination of a pre-clinical candidate for a novel target for idiopathic pulmonary fibrosis (IPF) in under 18 months.
AI-generated novel molecule for a novel target discovered with AI demonstrated efficacy in a broad therapeutic area and reached preclinical candidate stage in Idiopathic Pulmonary Fibrosis (IPF)

HONG KONG
Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
NEW YORK
345 Park Avenue South,
2nd Floor Suite 006 New York,
NY 10010
MONTREAL
1250 Rene-Levesque West,
Suite 3710, Montreal, Quebec,
Canada H3B 4W8
Subscribe to our news
By clicking the button you agree to our Privacy Policy